Can Trazodone Cause Restless Legs Syndrome?

Trazodone can trigger restless legs syndrome in some people, though published evidence suggests it happens rarely and the link is not as strong as with other antidepressants like SSRIs. The clearest documentation comes from individual case reports rather than large trials, so the risk appears to be low but real. What makes the situation tricky is that trazodone is often prescribed specifically for insomnia, and RLS itself is a major cause of sleeplessness, meaning the drug meant to help you sleep could, in uncommon cases, introduce a new obstacle to sleeping.

What the Published Evidence Actually Shows

The most detailed report in the medical literature describes a 39-year-old woman who was prescribed trazodone at 100 mg per day for insomnia. She experienced burning, tingling, and restlessness in her legs starting the very first night she took the medication. The sensations created an overwhelming urge to move her legs. Her doctors attributed the symptoms to trazodone and stopped the drug. Within one day of discontinuing it, her RLS symptoms disappeared entirely, and her insomnia also resolved.¹

Beyond individual case reports, a larger cross-sectional study looked at RLS prevalence among patients taking various antidepressants and found no significant difference in RLS rates based on which antidepressant a patient was using. About 3.2% of patients on antidepressant monotherapy were diagnosed with RLS, and roughly the same proportion of patients on dual antidepressant therapy had it.² That study concluded that depression and anxiety themselves were more strongly associated with RLS than any particular antidepressant was. In other words, if you have RLS while taking trazodone, the underlying mood disorder could be playing as big a role as the medication itself.

Trazodone does appear on lists of medications that have been flagged in case series as potential RLS triggers, alongside tricyclics, SSRIs, and SNRIs.³ But being on that list does not mean the risk is equal across all those drug classes. A systematic review of antidepressants and their effects on leg movements during sleep found that sedating antidepressants like trazodone did not seem to aggravate periodic limb movements, while SSRIs clearly did.⁴ Periodic limb movements are closely related to RLS and often occur alongside it, so that finding suggests trazodone sits in a lower-risk category compared to drugs like fluoxetine, sertraline, or paroxetine.

How Trazodone Could Disrupt Dopamine and Trigger Symptoms

RLS is fundamentally linked to dopamine signaling in the brain. The uncomfortable leg sensations and the irresistible urge to move are thought to arise when dopamine activity drops too low in certain brain circuits. Trazodone’s pharmacology is complex enough that it can plausibly interfere with these circuits, even though it is not primarily a dopamine-targeting drug.

One pathway involves serotonin. Trazodone boosts serotonergic activity, and research using brain imaging has found evidence that increased serotonin neurotransmission in the brainstem may worsen RLS, possibly by dampening dopamine signaling in the striatum and affecting motor and sensory neurons in the spinal cord.⁵ This serotonin-dopamine crosstalk is actually the same reason SSRIs can trigger RLS, though trazodone works differently from SSRIs at the receptor level.

There is also a more direct route. Trazodone blocks serotonin 5-HT2A receptors far more strongly than 5-HT2C receptors. Blocking 5-HT2A tends to decrease dopamine release, while the relative sparing of 5-HT2C adds another brake on dopamine. At higher doses, animal studies have shown that trazodone can directly block dopamine D2 receptors in the striatum. The net effect is a reduction in dopaminergic transmission that, in theory, could produce movement-related side effects.⁶ In extreme cases, this same mechanism has been reported to cause drug-induced parkinsonism, which involves similar dopamine deficiency. RLS would be a milder manifestation along the same spectrum of dopamine disruption.

Trazodone Versus SSRIs and Other Antidepressants

If you need an antidepressant and you are worried about RLS, the relative risk across different drug classes matters more than whether any single drug has ever been linked to a case. The picture that emerges from the available research is that trazodone sits in a middle zone: not as clean as bupropion, but considerably less problematic than the classic SSRIs.

A sleep study in children compared leg movement patterns across trazodone users, SSRI users, and controls without medication. Children on trazodone showed slightly higher leg movement rates than unmedicated children, but notably lower rates than those on SSRIs, and the pattern of movements was different as well.⁷ The systematic review mentioned earlier arrived at a similar conclusion for adults, finding that sedating antidepressants as a class did not appear to worsen periodic limb movements the way serotonin reuptake inhibitors did.⁴

Bupropion stands out as the antidepressant with the best track record for people with RLS. Early case reports found that a low dose rapidly and completely eliminated RLS symptoms in depressed patients within days of starting treatment.⁸ A randomized controlled trial later confirmed that bupropion does not exacerbate RLS symptoms and may be a reasonable first choice when an antidepressant is needed in someone who already has the condition.⁹ The likely explanation is straightforward: bupropion acts primarily on dopamine and norepinephrine rather than serotonin, so it sidesteps the serotonin-mediated dopamine suppression that appears to drive antidepressant-associated RLS.

Why Some People May Be More Susceptible

Given that millions of people take trazodone and RLS from the drug is clearly uncommon, the question becomes why certain individuals react this way when most do not. A few factors likely raise the odds.

The most intriguing recent finding involves how your body metabolizes trazodone. When trazodone breaks down in the liver, one of its major metabolic routes produces an active metabolite called mCPP. This metabolite is then cleared mainly by an enzyme called CYP2D6. People who are genetically poor metabolizers for CYP2D6 accumulate higher levels of mCPP relative to trazodone. A pharmacogenetic study found that CYP2D6 poor metabolizers had roughly nine times the odds of developing adverse drug reactions compared to normal metabolizers.¹⁰ The study looked at adverse reactions broadly rather than RLS specifically, but mCPP is known to have serotonergic activity, so higher mCPP levels could theoretically amplify the serotonin-dopamine interference that drives RLS symptoms. Around 5 to 10 percent of people of European descent are CYP2D6 poor metabolizers, and the proportion varies by ethnicity.

Iron status is another established risk factor. Low iron stores are one of the strongest predictors of RLS in general, regardless of medication use. Current clinical guidelines recommend checking serum ferritin when someone develops RLS, and supplementation is considered a first-line treatment when ferritin is below a certain threshold.¹¹ A person with borderline iron stores who starts trazodone may be more vulnerable to developing symptoms than someone with robust iron levels. This is especially relevant for premenopausal women, vegetarians, people with kidney disease, and frequent blood donors, all of whom are more likely to have low ferritin.

The dose also matters. The dopamine-blocking effects of trazodone appear to be dose-dependent, with animal studies showing more pronounced D2 receptor blockade at higher doses.⁶ Trazodone is used at very different doses depending on the indication: 25 to 100 mg for insomnia, versus 150 to 400 mg or more for depression. Someone taking higher antidepressant doses may face more dopaminergic disruption than someone using a low sleep-aid dose. That said, the published case report involved a patient who developed symptoms at just 100 mg, so even moderate doses are not risk-free in susceptible individuals.¹

Recognizing Drug-Induced RLS

One challenge is that RLS symptoms can look like other medication side effects, and vice versa. Akathisia, a general feeling of inner restlessness and inability to sit still, can be caused by many psychiatric medications and overlaps substantially with RLS. The key distinction is where the discomfort is concentrated: RLS produces specific sensory symptoms in the legs, including creeping, tingling, burning, or aching, with a strong urge to move the legs specifically. Akathisia tends to be a whole-body restlessness without the focal leg sensations. Both conditions are worse at rest and improve with movement, which makes the overlap confusing.

Timing is one of the most useful diagnostic clues. Drug-induced RLS tends to appear within the first few days of starting a new medication or increasing the dose. In the published trazodone case, symptoms began the very first night. If you have been on a stable dose of trazodone for months and leg symptoms suddenly appear, the medication is less likely to be the sole cause, though changes in iron status or the addition of other medications could still unmask a latent vulnerability.

The other practical clue is what happens when the drug is stopped. In drug-induced cases, symptoms typically resolve quickly once the offending medication is removed. The reported trazodone case saw complete resolution within a single day. If stopping trazodone does not relieve your symptoms within a week or two, you may have primary RLS that was either present before the medication or developed independently.

What to Do If You Develop Symptoms While on Trazodone

The first step is not to stop the medication abruptly without talking to whoever prescribed it. Trazodone discontinuation can cause its own withdrawal-like symptoms, and the decision about whether to stop, switch, or adjust the dose should involve your prescriber. That said, it is worth bringing up the concern promptly rather than waiting for a scheduled follow-up, especially if the symptoms are severe enough to keep you from sleeping, since that defeats the purpose of the medication.

If you and your doctor decide trazodone is the likely cause, switching to a different medication is the most direct solution. As noted earlier, bupropion is the antidepressant most consistently shown not to worsen RLS and may even improve it. For insomnia specifically, the options are broader, since many sleep aids work through mechanisms unrelated to serotonin. Your prescriber will weigh the original reason you were prescribed trazodone against the alternatives available.

Regardless of whether you stay on trazodone or switch, getting your iron levels checked is worthwhile. Some medications used to treat insomnia and depression can unmask or exacerbate RLS in people whose iron stores are already low.¹² If your ferritin is low, iron supplementation might resolve the RLS even if you continue the medication.

How RLS Is Treated When It Persists

If your leg symptoms continue after addressing the medication question, you may have primary RLS that needs its own treatment. The treatment landscape for RLS has shifted considerably in recent years. Current guidelines from the American Academy of Sleep Medicine endorse gabapentinoids, a class that includes gabapentin, pregabalin, and gabapentin enacarbil, as first-line pharmacologic therapy.¹³ These drugs work through calcium channels rather than dopamine, which avoids the augmentation problem that plagued older dopamine-based treatments.

Iron supplementation is the other first-line approach. Guidelines recommend starting oral ferrous sulfate when serum ferritin is at or below 100 ng/mL or transferrin saturation is under 20%, with intravenous iron as an option for faster results or when oral iron is not tolerated.¹¹ The ferritin threshold for treatment may surprise you, since many lab reports flag values as “normal” at levels well above the threshold that can still contribute to RLS. A ferritin of 40 ng/mL, for example, would not be flagged as low on most lab reports, but it falls well below the treatment threshold for RLS.

Dopamine agonists like pramipexole and ropinirole, which were once the go-to treatment, are now recommended with more caution. They work well initially but carry a risk of augmentation, a paradoxical worsening of symptoms over time that can leave you worse off than before treatment. The 2025 guidelines specifically discourage routine use of dopamine agonists as first-line therapy.¹³ For severe or refractory cases, they remain an option, but typically after gabapentinoids and iron have been tried.¹⁴

The Relationship Between Depression, Insomnia, and RLS

There is a layer of complexity here that goes beyond the medication itself. Depression, insomnia, and RLS are all interconnected in ways that make it hard to tease apart cause and effect. The cross-sectional study that found no significant difference in RLS rates across antidepressant types did find that major depressive disorder and anxiety disorder themselves were associated with higher RLS rates.² This raises a frustrating possibility: some people who blame their antidepressant for causing RLS may actually have RLS driven by the mood disorder the antidepressant was prescribed to treat.

Sleep deprivation from untreated insomnia can itself worsen RLS, creating a vicious cycle. Trazodone is frequently prescribed as a sleep aid precisely because it is sedating at low doses. If stopping it resolves leg symptoms but brings back insomnia, and the insomnia then triggers RLS on its own, the solution is not obvious. This is where individualized care from a sleep specialist or psychiatrist familiar with both conditions becomes genuinely important, because the right answer depends on your specific clinical picture rather than any general rule about trazodone and RLS.

For people who do well on trazodone and have no leg symptoms, there is no reason to worry preemptively. The overall evidence suggests trazodone is among the better-tolerated antidepressants when it comes to RLS risk, sitting well below SSRIs and SNRIs. But if you notice new leg discomfort after starting it, especially sensations that arrive in the evening or at rest and improve when you move around, that is a signal worth mentioning to your doctor sooner rather than later.

1
PubMed. Restless Legs Syndrome Due to the Use of Trazodone: A Case Report
2
PubMed Central. Restless Legs Syndrome: Associated with Major Depressive Disorder and Anxiety Disorder But Not with Antidepressant Use
3
PubMed Central. Medications Associated with Restless Legs Syndrome: A Case Control Study in the US Renal Data System (USRDS)
4
PubMed. The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review
5
PubMed. Availability of brain serotonin transporters in patients with restless legs syndrome
6
PubMed Central. Trazodone-induced parkinsonism in a middle-aged male: A case report
7
PubMed Central. Trazodone affects periodic leg movements and chin muscle tone during sleep less than selective serotonin reuptake inhibitor antidepressants in children
8
PubMed. Bupropion may improve restless legs syndrome: a report of three cases
9
PubMed. Bupropion and restless legs syndrome: a randomized controlled trial
10
PubMed Central. CYP2D6 Phenotype as a Predictor of Adverse Drug Reactions in Patients Treated With Trazodone: An Explorative Pharmacogenetic Study
11
JAMA. Restless Legs Syndrome: A Review
12
Taylor & Francis Online (Current Medical Research and Opinion). Diagnosis, comorbidities, and management of restless legs syndrome
13
PubMed Central. The evolving treatment landscape of restless legs syndrome
14
CHEST. Sleep: How I Do It Treating Severe Refractory and Augmented Restless Legs Syndrome